Ovarian hyperstimulation syndrome (OHSS) Pregnancy and Childbirth Ovarian hyperstimulation syndrome (OHSS)
Conditions
Interventions
1. Long mid luteal GnRH agonist protocol, 0.1 mg triptorelin SC. (Decapeptyl
Ferring
Germany) has been used for pituitary down regulation in both groups
2. Once pituitary down regulation has been confirmed, controlled ovarian hyperstimulation (COH) was started using fixed dose of HMG,
n=100), received 0.25 mg daily for 8 days and non-cabergolone group (Group II
n=100), did not receive cabergoline
5. Transvaginal guided oocyte retrieval was performed 34 - 36 hours later
6. Both groups have been administrated 500 ml of hydroxyethyl starch (HES) over 30 minutes
Cox Pharmaceuticals, Whiddon Valley, UK)
9. Haemoconcentration, presence of ascitis, measuring the perpendicular diameter of free fluid in Douglas Pouch, and the ovarian volume have been reported in b
Sponsors
Samir Abbas Center (Saudi Arabia)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. 200 infertile couples undergoing ICSI and at risk of developing OHSS have been included between January 2007 and July 2009 2. The risk to develop OHSS has been defined as follows: 2.1. Dopamine E2 level on day of hCG > 3500 pg/ml 2.2. With = 20 follicles > 12 mm
Exclusion criteria
Exclusion criteria: Patients with dopamine E2 =5000 pg/ml
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence, onset and severity of OHSS | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Oocyte recovery rate 2. Number of mature oocytes 3. Fertilization rate 4. Clinical pregnancy rate (defined as presence of fetal heart pulsation 2 weeks after a positive ß-HCG test) | — |
Countries
Saudi Arabia
Outcome results
None listed